Measurement of apoptosis using M30 in culture media of cell lines treated with anti-cancer agents.
10.5468/kjog.2010.53.5.401
- Author:
Sang Ho PARK
1
;
Hyun Sung KWACK
;
Ki Sung RYU
;
Young LEE
;
Ku Taek HAN
Author Information
1. Clinical Research Laboratory, St. Mary's Hospital, The Catholic University of Korea School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Apoptosis;
M30 antigen;
HeLa cells;
OVCAR-3
- MeSH:
Apoptosis;
Camptothecin;
Cell Line;
Cisplatin;
Culture Media;
Enzyme-Linked Immunosorbent Assay;
Fluorescent Antibody Technique;
HeLa Cells;
Humans;
Isothiocyanates;
Paclitaxel
- From:Korean Journal of Obstetrics and Gynecology
2010;53(5):401-409
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: We investigated a possible use of the induced apoptosis as a biomarker in the cells and their media treated with commonly used anti-cancer agents in gynecologic malignancies. METHODS: After treatments with low and high concentrations of paclitaxel, cisplatin, and camptothecin in HeLa and OVCAR-3 cells, the levels of M30 antigen were detected in the cells and their media by immunofluorescence staining and ELISA methods, respectively. RESULTS: The percentages of M30-fluoresein isothiocyanate (FITC) positive cells in HeLa and OVCAR-3 cells treated with paclitaxel, cisplatin, and camptothecin were 4.3% vs 18.1% vs 34.87% and 4.07% vs 18.6% vs 32.63%, 4.3% vs 17.87% vs 32.38% and 4.07% vs 16.83% vs 32%, and 4.3% vs 16.75% vs 31.3% and 4.07% vs 15.18% vs 29.9% in control, low dose, and hight dose groups, respectively (P<0.001). M30 antigen levels (U/L) measured in culture media of HeLa and OVCAR-3 cells treated with paclitaxel, cisplatin, and camptothecin were 53.03 vs 101.53 vs 355.59 and 86 vs 114.41 vs 412.04, 53.03 vs 79.84 vs 327.64 and 86 vs 125.44 vs 385.09, and 53.03 vs 88.41 vs 295.005 and 86 vs 108.42 vs 263.1 in control, low dose, and hight dose groups, respectively (P<0.001). CONCLUSION: Our results obtained in this preclinical study suggests that measurement of the levels of M30 antigen may help to predict the clinical responses and to select the effective anti-cancer agents in clinical settings, rapidly and quantitatively.
